Understand the source comparison
LL-37 Safe Side Effects: Route Comparison
The table below compares adverse event profiles, systemic exposure, and practical safety considerations across the four primary LL-37 administration routes studied in published research. Route selection should align with research objectives while prioritizing
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares adverse event profiles, systemic exposure, and practical safety considerations across the four primary LL-37 administration routes studied in published research. Route selection should align with research objectives while prioritizing the lowest-risk approach that achieves the desired pharmacokinetic profile.
- Subcutaneous (1–5 mg)
- Injection-site erythema (30–40%), mild edema (15–20%), transient warmth (25%)
- 0.5–2 µg/mL plasma
- 45–90 minutes
- 1–2× physiological
- Optimal for most research protocols. Localized reactions self-resolve within 24 hours, systemic exposure remains within safe margins
- Intramuscular (1–5 mg)
- Muscle soreness (25–35%), injection-site erythema (20–30%), delayed onset muscle tenderness (10%)
- 0.8–3 µg/mL plasma
- 30–60 minutes
- 1.5–3× physiological
- Faster systemic absorption than SC. Useful for acute immune response studies but slightly higher discomfort profile
- Topical (0.1–1.0 mg/mL)
- Transient stinging (5–10%), mild erythema (2%), contact dermatitis (<1%)
- <0.05 µg/mL plasma (negligible)
- No systemic peak
- No systemic elevation
- Safest route with virtually no systemic effects. Ideal for wound healing and dermatological research
- Intravenous (0.1–0.5 mg/kg)
- Transient hypotension (10–15%), flushing (5%), headache (3–5%)
- 5–15 µg/mL plasma
- 5–10 minutes
- 3–10× physiological
- Highest-risk route. Immediate systemic exposure requires cardiovascular monitoring, not recommended for standard protocols